Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cancer Res. 2014 Sep 18;74(21):6341–6351. doi: 10.1158/0008-5472.CAN-14-1052

Figure 4. Oncogenic activities of RBP and STRA6 are mediated by STAT3.

Figure 4

a) Top: Representative immunoblots of phosphorylated STAT3 (pSTAT3) and total STAT3 in HCT116 stably expressing STRA6 and treated with vehicle (−) or holo-RBP (1 μM, 15 min.). Bottom: quantitation of immunoblots. b) Immunoblots of pSTAT3 and STAT3 in SW480 cells stably expressing e.v. or STRA6 shRNA treated with vehicle (−) or holo-RBP (1 μM, 15 min.). c) Levels of mRNAs of denoted genes in HCT116 cells stably expressing e.v. or STRA6 treated with 1 μM holo-RBP for 4 h. *p<0.05 vs. e.v.-expressing untreated cells, **p<0.05 vs. e.v.-expressing holo-RBP-treated cells. d) Levels of mRNAs of denoted genes in SW480 cells stably expressing e.v. or STRA6 shRNA treated with 1 μM holo-RBP for 4 h. *p<0.05 vs. e.v.-expressing untreated cells. e) Levels of mRNAs of denoted genes in SW480 cells pre-treated with 10 μM AG490 for 24 h. and then treated with 1 μM holo-RBP for 4 h. *p<0.05 vs. e.v.-expressing untreated cells. f) Immunoblots of pSTAT3 and STAT3 in HCT116 stably expressing e.v. or a vector encoding STAT3-DN treated with 1 μM holo-RBP for 15 min. *p<0.05 vs. e.v.-expressing untreated cells. g, i) Levels of c-Fos mRNA in HCT116 cells stably expressing e.v. or STAT3-DN (g) or STAT3 shRNA (i). Cells were treated with 1 μM holo-RBP for 4 h. *p<0.05 vs. e.v.-expressing untreated cells. h) 24 h. BrdU incorporation in HCT116 cells stably expressing e.v. or vector encoding STAT3-DN. Cells were treated with vehicle or 1 μM holo-RBP. *p<0.05 vs. e.v.-expressing untreated cells. j) Rates of migration of HCT116 cells expressing e.v. or a vector encoding STAT3 shRNA and treated with 1 μM holo-RBP. *p<0.05 vs. e.v.-expressing untreated cells. All data are mean±S.E.M. (n=3).